替吉奥治疗老年晚期胃癌的临床观察

Clinical Study of S-1 for Elderly Advanced Gastric Cancer

目的观察口服替吉奥治疗老年晚期胃癌的疗效和不良反应。方法 39例老年进展期胃癌患者,口服替吉奥胶囊,完成2个周期后评价疗效和不良反应。结果全组39例客观疗效为,CR 1例,PR 12例、SD 11例、PD 15例。有效率(CR+PR)33.3%,肿瘤控制率为(CR+PR+SD)61.5%。主要不良反应为骨髓抑制,胃肠道反应,色素沉着等。结论替吉奥是治疗进展期胃癌安全、有效的药物,特别适宜于老年体弱的患者。

Objective To evaluate the efficacy and toxicity of S-1 for elderly advanced gastric cancer. Method Thirty-nine elderly patients with advanced gastric cancer were treated with S-1 capsule. The evaluation of efficacy and toxicity were performed on all patients after 2 cycles. Results Of the 39 patients,there were 1（2.5%） complete remission（CR）,12（30.8%）partial remission（PR）, ll（28.2%）stable disease（SD）, and 15（38.5%）progression disease（PD）. The total response rate was 33.3%. The disease control rate（DCR）was 61.5%. The major toxicities included myelo suppression,gastrointestinal reaction and cutaneous pigmentation. Conclusion S-1 is safe and effective in the treatment of advanced gastric cancer, especially for patients old and frail.